Hyponatremia
Conditions
Keywords
electrolyte disorder, Bone Metabolism, Sodium Levels
Brief summary
In this study, the possible role of serum sodium concentration and its changes on bone markers in hospitalized, hyponatremic patients is determined. Therefore, it is investigated whether in hospitalized, hyponatremic patients the level of carboxy-terminal collagen crosslinks (CTX) is modified by changes in plasma sodium concentration, independently from the aetiology of hyponatremia.
Interventions
OTHERblood sampling
blood sampling for measurement of bone markers after a fasting period of at least 6 hours
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Adult hospitalized patients with non-hypertonic hyponatremia: serum sodium \< 130 mmol/l, serum osmolality \< 300 milliosmol /kg * age 18 to 99-year-old * Informed consent as documented by signature
Exclusion criteria
* Severe symptomatic hyponatremia in need of intensive care treatment * Hypertonic hyponatremia with serum osmolality \> 300 mOsm/kg * End of life care (palliative treatment) * End stage kidney disease (dialysis) * Acute liver failure * Wernicke encephalopathy * Hepatic encephalopathy during last 2 months * Hepato-renal syndrome * Any bone disease requiring treatment in the last three years * History of fragility fractures * Pre-menopausal women * Hypogonadism (diagnosed before hospitalization) * Hyperthyroidism * Steroid therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in carboxy-terminal collagen crosslinks (CTX) levels | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | CTX level (pg/ml) and its dynamic within 10 days of hospitalization |
| Change in plasma sodium level | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | serum sodium levels (milliequivalents per liter (mEq/L) and its dynamic within 10 days of hospitalization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in procollagen type I N propeptide (PINP) (PINP) levels | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | PINP (ng/mL) levels and their dynamic within 10 days of hospitalization |
| Change in sclerostin | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | Sclerostin (pg/ml) levels and their dynamic within 10 days of hospitalization |
| Change in parathyroid hormone (PTH) | changes from baseline (day 1) to day 10 after inclusion in the study | PTH (pg/ml) levels and their dynamic within 10 days of hospitalization |
| Change in 25-hydroxy-vitamin D3 | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | 25-hydroxy-vitamin D3 (ng/ml) levels and their dynamic within 10 days of hospitalization |
| Changes in bone specific alkaline phosphatase (bAP) | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | bAP levels and their dynamic within 10 days of hospitalization |
| Change in phosphate levels | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | Phosphate(mg/dl) levels and their dynamic within 10 days of hospitalization |
| Numbers of falls | numbers of falls within 30 days after enrolment | telephone interview will be performed to collect data about occurrence and numbers of falls within 30 days after enrolment |
| Numbers of fractures | Numbers of fractures within 30 days after inclusion in the study | telephone interview will be performed to collect data about occurrence and numbers of fractures within 30 days after enrolment |
| Change in calcium | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | Calcium (mg/dl) levels and their dynamic within 10 days of hospitalization |
| Change in osteocalcin | baseline blood exam on day 1 after inclusion and further blood collections at day 10 (+/-3 days) or at discharge, if discharge will be earlier | Osteocalcin (ng/mL) levels and their dynamic within 10 days of hospitalization |
Countries
Switzerland
Outcome results
None listed